Farmacocinetica

 Primo studio farmacocinetico della FLU, utilizzando differenti vie di somministrazione, in due specie animali di interesse veterinario: cane e gatto.

 La FLU mostra un buon profilo di sicurezza e tollerabilità.

 La somministrazione IV a 5 mg/Kg presenta elevate concentrazione plasmatiche associabili ad effetti collaterali (nel cane) risolvibili in pochi minuti.

 La F% POIR nel cane e nel gatto ha mostrato valori similari, ma nettamente inferiori rispetto a valori di F% riscontrati in letteratura nel uomo.

 La somministrazione POIR 5mg/Kg e la POPR 200 mg/soggetto hanno mostrato profili farmacocinetici molto simili. La somministrazione POIR è preferibile per il prezzo inferiore del farmaco in commercio.

 La somministrazione RC è sconsigliata per la bassa F%.

 5 mg/Kg di FLU risultano essere una dose valida per iniziare nuovi studi di efficacia nella specie canina e felina

Queste caratteristiche rendono il presente studio il primo step di ulteriori approfondimenti per un eventuale utilizzo della FLU in ambito clinico veterinario.

- 69 -

- 70 -

Abrams SM, Baker LR, Crome P, White AS, Johnston A, Ankier SI, Warringston ST, Turnur P, Nieb HG. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgraduate Medical Journal, 1988. 64(751): 361-363 Anonymus 2011. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009

Bonnie D. Clinical pain management techniques for cats. Clinical Techniques in small animal practice, 2002. 17(4): 151-157

Bradshaw A. Price. Rectal suppository insertion: the reliability of the evidence as a basis for nursing practice. Journal of Clinical Nursing, 2007.16: 98-103

Capuano A, De Corato A, Treglia M, Trigalli G, Navarra P. Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol. Pharmacology Biochemistry and Behavior, 2011. 97: 544-550

Carlsson KH & Jurna I. Depression by flupirtina, a novel analgesic agent, of motor and sensory response of the nociceptive system in rat spinal cord. European Journal of Pharmacology, 1987. 143: 89-99

Chen X, Zhong D, Xu H, Schug B, Blume H. Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 2001. 755: 195-202

Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of drugs in humans. Pharmaceutical Research, 2000. 17: 135-140

Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sík A, De Koninck P, De Koninck Y. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature, 2003. 424:938-942

Devulder J. Flupirtine in pain management pharmacological properties and clinical use. CNS Drug, 2010. 24: 867-881

Evans HE, De Lahunta A. Miller’s anatomy of the dog, IV ed., Elsevier, St. Louis, MO, 2012

Friedel HA & Fitton A. Flupirtine: a review of its pharmacological properties on therapeutic efficacy in pain states. Drugs 1993. 45: 548-569

Fox SM. Chronic pain in small animal mediocre. Hanson 2010 Pain Therapeutics.USA, 2014

Gibson KR, Cox PJ, Stevens E, Winchester WS, Gerlach AC, Maarrew BE, Butt RP. Ion channel modulators. Alleton C

Giorgi M. Veterinary pharmacology: is it still pharmacology's cinderella? Clinical and Experimental Pharmacology, 2012. 2

- 71 -

Giorgi M, Meizler A, Mills PC. Pharmacokinetics of the novel atypical opiod tapentadol folloeing oral and intravenous administration in dogs. Veterinary Journal, 2012. 194: 309- 313

Giorgi M & Owen H. Flupirtine: a human drug with potential for use in the veterinary field. American Journal of Animal and Veterinary Sciences, 2012. 213-217

Giorgi M, Saccomanni G, Lebkowska-Wieruszewska B, Cezary K. Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. Veterinary Journal, 2009. 180: 253-255

Giorgi M & Yun H. Pharmacokinetics of mirtazapine and its main metabolites in beagle dogs: a pilot study. Veterinary Journal, 2012. 192: 239-241

Goodchild CS, Kolosov A, Tucker AP. Combination therapy with flupirtine and opioid: studies in rat pain models. Pain Medicine, 2008. 9: 928-938

Gordon R, Duane Sofia R, Diamatis W. Effect of flupirtine maleate on the nociceptive pathway, EEG, evoked potentials and synaptic reflex in laboratory animals. Postgraduate Medical Journal, 1987. 63: 49-55

Harish S, Bhuvana K, Girish M, Bengalork Kumar TN. Flupirtine: Clinical pharmacology journal of anaesthesiology clinical pharmacology, 2012. 28: 172-77

Henke J & Erhardt W. Terapia del dolore negli animali da compagnia. Milano. Ed. italiana Lachin A. Masson, 2006

Herrmann WM, Hiersemenzel R, Aigner M, Lobisch M, Riethmüller-Winzen H, Michel I. Longterm tolerance of flupirtine: open multicenter study over one year. Fortschritte der Medizine, 1993. 111: 266-270

Herrmann WM, Kern U, Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgraduate. Medical. Journal, 1987. 63: 87-103

Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgraduate Medical Journal, 1987. 63: 71-79

Hirschowitz BI. Clinical course of nonsurgically treated zollinger-ellison syndrome. Frontiers of Gastrointestinal research, 1994. 23: 360-360

Hlavica P & Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arznei- mittelforschung, 1985. 35(1): 67-74

Johnson JW & Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 1987. 325: 529-531

Kandasamy K, Gowdra VS, Nammalvar H. Govindarajan. Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. Arzneimittel-Forschung/Drug Research, 2011. 61 (12): 693-699

- 72 -

Katzung BG, Master SB, Treaver AS. Farmacologia generale e clinica. Perugia, VIII edizione italiana. Piccin, 2011

Klave C & Maschk E. Flupirtine: paharmacology and clinical applications of a nonopioid analgesic and partially neuroprotective compound. Drug Evalvations, 2009. 10: 1459- 1500

Kolosov A, Goodchild CS, Williams ED, Cook I. Flupirtine enhances the anti- hyperalgesic effects of morphine in a rat model of prostate bone metastasis. Pain Medicine, 2012. 13: 1444-1456

Korenhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist Amantadine; Neuropharmacology, 1995. 13: 713-721

Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D. Ru¨ther E.Opening of neuronal K channels by flupirtine. Fortschritte der Neurologie Psychiatrie, 1999. 67: 466-475 Kumar R, Keshri UP, Sharma J. Flupirtine: a mini review: Journal of Drug Delivery & Therapeutics, 2013. 3(6): 113-116

Lamont LA, Tranquilli WJ, Mathews KA. Adjunctive analgesic therapy. Veterinary Clinicals of North America (Small Animal Practi), 2000. 30: 805-813

Lavy E, Soldani G, Neri D, Prise U, Brandriss A, Chaimd B, Giorgi M. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in beagle dogs. The Veterinary Journal, 2011. 189: 336-340

Leucuta SE. Drug delivery systems with modified release for systemic and biophase bioavailability. Current Clinical Pharmacology, 2012. 7: 282-317

Luben V, Muller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine: Results of a double-blind study versus tramadol. Fortschritte der Medizin, 1994. 112: 282-6 Maier AY, Liu A, Scholze Westhoff TH, Tepel M. Green urine following exposure to flupirtine. American. Journal of Kidney Disease, 2010. 56: 1014-1015

Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block byMg of NMDA response spinal cord neurones. Nature, 1984. 309: 261-263

Mastronardi P, D’Onofrio M, Scanni E, Pinto M, Frontespezi S, Ceccarelli MG, Bianchi F, Mazzarella B. Analgesic activity of flupirtine maleate: A controlled double-blind study with diclofenac sodium in orthopaedics. Journal of International Medical Researce, 1988. 16: 338-48

Mathews KA. Neuropathic pain in dogs and cats: if only they could tell us if they hurt. Veterinary Clinicals of North America (Small Animal Practice), 2008. 38: 1365-1414 McBain CJ & Mayer ML. N-Methyl-d-aspartic acid receptor structure and function. Physiological Reviens, 1994. 74: 723-760

McMahon FG, Arndt WF, Newton JJ, Montgomery PA, Perhach JJ. Clinical experience with flupirtine in the U.S. Postgraduate. Medical journal, 1987. 63: 81-85

- 73 -

Mersky H. Classification chronic pain. Pain, 1983; 3:1

Methling K, Reszka P, Lalk M, Vrana O. Scheuch E.Siegmund W Terhaag B Bednarski PJ. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metabolism and Disposotion, 2009. 37(3): 479-93

Mori H & Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology, 1995. 34: 1219-1237

Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschritte der Medizin Originalien, 2003. 121(1): 11-18

Narang P, Tourville JF, Chatterji DC, Gallelli JF. Quantification of flupirtinie and its active acetylated metabolite by reversed-phase high-performance liquid chromatography using fluorometric detection. Journal of Chromatography, 1984. 305: 135-143

Nicke B. The antinociceptive activity of flupirtine: a structurally new analgesic. Postgraduate Medical Journal, 1987. 63: 19-28

Nicoli RA. The coupling of neurotransmitter receptors to ion channels in the brain. Science, 1988. 241:545-551

Niebch G, Borbe HO, Hummel T, Kobal G. Dose-proportional plasma levels of the analgesic flupirtine maleate in man. Arzneimittel-Forschung/Drug Research, 1992. 42(11): 1343-1345

North RA. Twelfth Gaddum memorial lecture. Drug receptors and the inhibition of nerve cells.Br. Journal Pharmacology, 1989. 98: 13-28

Obermeier K, Niebch G, Thiemer K. Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog. Arzneimittel-Forschung/Drug Research, 1985. 35: 60-67

Osborne NN, Cazevieille C, Wood JP, Nash MS, Pergande G, Block F, Osinski C, Schward M. Flupirtine, a non-opioid centrally acting analgesic, acts as an NMDA antagonist. General Pharmacology, 1998. 30: 255-263

Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. Veterinary Clinics of North America (Small Animal Practi), 2008. 38: 1243- 1266

Pascoe PJ. Opioid analgesics. Veterinary Clinics of North America (Small Animal Practi), 2000. 30: 757-772

Perkowski SZ & Wetmore LA. The Science and Art ofAnalgesia. In: Gleed RD e Ludders JW: Recent advancesin Veterinary anestesia and analgesia: companion animals. International Veterinary Information Service (IVIS) (www. ivis.org), Ithaca, New York 2006

Raffa R & Pergolizzi JV. The evolving understanding of the analgesic mechanism of action of flupirtine. Journal of clinical pharmacy and therapeutics, 2012. 37:4-6

- 74 -

Satheesh B, Sree Ganesh KK, Saravanan D, Ramakant KG. Sivananthan S. Quantification of flupirtine and its related compounds in pharmaceutical dosage forms by UPLC. Journal of Pharmacy Research, 2012. 5: 2694-2699

Schuster M, Schwarz M, Block F, Pergande G, Schmidt WJ. Flupirtine: a review of its neuroprotective and behavioural properties. CNS Drug Reviw, 1998. 4: 149-164

Schward M, Block F, Pergande G. N-metyl-D-aspartate(NMDA)- mediated muscle relaxant of flupirtina in rats. Neuroreport, 1994. 5: 1981-1984

Singal R. Role of Flupirtine in the Treatment of Pain-Chemistry and its Effects Medica- a journal of clinical medicine, 2012. 7(2): 163-166

Szelenyi I, Nickel B, Borbe HO. Brune K. Mode of antinociceptive action of flupirtine in the rat. British journal of pharmacology, 1989. 97(3): 835-842

Thomson AM, West DC, Lodge D. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine. Nature, 1985. 313: 479-481

Thompson SM, Capogna M, Scanzani M. Presynaptic inhibition in the hippocampus. Trends Neuroscience, 1993. 16: 222-227

Treudler R, Pohle K, Simon JC. Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs. European Journal of Clinical Pharmacology, 2011. 67: 961- 963

Waldhoer M, Bartlett SE, Whistler JL. Opioid Receptors. Annual Review of Biochemistry, 2004. 73: 953-990

Wu LG & Saggau P. Presynaptic inhibition of elicited neurotransmitter release. Trends Neurosciences, 1997. 20: 204-212

Zhong D, Chen X, Gu J, Li X, Guo J. Application of liquid chromatography–tandem mass spectrometry in drug and biomedical analyses. Clinica Chimica Acta 2001. 313: 147-150